[
    {
        "file_name": "HarpoonTherapeuticsInc_20200312_10-K_EX-10.18_12051356_EX-10.18_Development Agreement_Option Agreement.pdf",
        "perturbation": [
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "10.2\tAdditional Representations and Warranties of Harpoon. Except as set forth on Schedule 10.2,\nHarpoon further represents and warrants to AbbVie, as of the Effective Date, as follows:\n\n10.2.1\tAll Harpoon Patents existing as of the Effective Date are listed on Schedule 10.2.1 (the\n“Existing Patents”). To Harpoon’s Knowledge, all Existing Patents existing as of the Effective Date are subsisting and, to\nHarpoon’s Knowledge, are not invalid or unenforceable, in whole or in part, are being diligently prosecuted in the applicable patent\noffices in the Territory in accordance with Applicable Law, and have been filed and maintained properly and correctly in all material\n\n10.2.3\tHarpoon is (a) the sole and exclusive owner of the entire right, title and interest in the\nExisting Patents listed on Schedule 10.2.1, Part A (the “Owned Patents”) and the Harpoon Know-How and (b) the sole and\nexclusive licensee of the Existing Patents listed on Schedule 10.2.1, Part B (the “In-Licensed Patents”) which are subject to valid\nand enforceable in-license agreements, in each case ((a) and (b)) free of any encumbrance, lien, or claim of ownership by any Third\nParty. Harpoon is entitled to grant the licenses specified herein. The Owned Patents and In-Licensed Patents represent all of the\nExisting Patents.",
                "changed_text": "10.2\tAdditional Representations and Warranties of Harpoon. Except as set forth on Schedule 10.2, Harpoon further represents and warrants to AbbVie, as of the Effective Date, as follows:\n\n10.2.1\tAll Harpoon Patents existing as of the Effective Date are listed on Schedule 10.2.1 (the “Existing Patents”). To Harpoon’s Knowledge, all Existing Patents existing as of the Effective Date are subsisting and, to Harpoon’s Knowledge, are not invalid or unenforceable, in whole or in part, are being diligently prosecuted in the applicable patent offices in the Territory in accordance with Applicable Law, and have been filed and maintained properly and correctly in all material\n\n10.2.3\tHarpoon may not be the sole and exclusive owner of the entire right, title and interest in the Existing Patents listed on Schedule 10.2.1, Part A (the “Owned Patents”) and the Harpoon Know-How and (b) Harpoon may not be the sole and exclusive licensee of the Existing Patents listed on Schedule 10.2.1, Part B (the “In-Licensed Patents”) which are subject to valid and enforceable in-license agreements, in each case ((a) and (b)) free of any encumbrance, lien, or claim of ownership by any Third Party. Harpoon is entitled to grant the licenses specified herein. The Owned Patents and In-Licensed Patents may or may not represent all of the Existing Patents.",
                "explanation": "The original text stated that Harpoon **is** the sole owner/licensee of patents. The modified version **adds uncertainty** by using \"may not be\", making the ownership unclear and potentially conflicting with the grant of rights in Article 5. This will also add uncertainty to which of Harpoon's patents AbbVie can exploit.",
                "location": "ARTICLE 10"
            },
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "3.2.3 License Option Exercise Notice. Upon the Effective Date, Harpoon hereby grants to AbbVie the exclusive right, but not the obligation, to obtain the licenses set forth in Section 5.1.3 (the “License Option”). AbbVie shall have the right to exercise its License Option by providing written notice of such election to Harpoon (“License Option Exercise Notice”) at any time on or after the Effective Date and on or prior to the date that is [***] from AbbVie’s receipt of the Opt-In Development Report containing all items required pursuant to Section 1.112, as such period may be extended pursuant to Section 3.2.1 (the “License Option Period”). If AbbVie does not provide a License Option Exercise Notice within the License Option Period, then (a) Harpoon shall have no further obligations to perform any Initial Development Activities, (b) AbbVie’s License Option shall expire, and this Agreement shall terminate in accordance with Section 12.1.1, and (c) AbbVie shall have no further rights in connection with Licensed Compounds of the Licensed Products.",
                "changed_text": "3.2.3 License Option Exercise Notice. Upon the Effective Date, Harpoon hereby grants to AbbVie the exclusive right, but not the obligation, to obtain the licenses set forth in Section 5.1.3 (the “License Option”). AbbVie shall have the right to exercise its License Option by providing written notice of such election to Harpoon (“License Option Exercise Notice”) at any time on or after the Effective Date and on or prior to the date that is [***] from AbbVie’s receipt of the Opt-In Development Report containing all items required pursuant to Section 1.112, as such period may be extended pursuant to Section 3.2.1 (the “License Option Period”). If AbbVie does not provide a License Option Exercise Notice within the License Option Period, then (a) Harpoon shall have no further obligations to perform any Initial Development Activities, (b) AbbVie’s License Option may still be valid, and this Agreement may or may not terminate in accordance with Section 12.1.1, and (c) AbbVie may still have further rights in connection with Licensed Compounds of the Licensed Products.",
                "explanation": "Original text said if AbbVie fails to exercise its right, AbbVie's License Option shall expire, and this Agreement shall terminate in accordance with Section 12.1.1, and AbbVie shall have no further rights in connection with Licensed Compounds of the Licensed Products. The modified text adds uncertainty. It added words like may or may not, or may still. This makes it hard to define in what situation does the initial clauses apply.",
                "location": "ARTICLE 3"
            },
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "3.8 Regulatory Matters.\n\n3.8.1 Pre-Exercise Regulatory Activities. Prior to the License Option Exercise Closing Date, the following shall apply:\n(a)\tHarpoon shall have the sole right and responsibility to prepare, obtain and maintain all INDs necessary to perform its obligations under the Initial Development Plan, and to conduct communications with the applicable Regulatory Authorities with respect to such INDs",
                "changed_text": "3.8 Regulatory Matters.\n\n3.8.1 Pre-Exercise Regulatory Activities. Prior to the License Option Exercise Closing Date, the following may or may not apply:\n(a)\tHarpoon may or may not have the sole right and responsibility to prepare, obtain and maintain all INDs necessary to perform its obligations under the Initial Development Plan, and to conduct communications with the applicable Regulatory Authorities with respect to such INDs",
                "explanation": "The original text stated that Harpoon **has** the sole right and responsibility to prepare, obtain and maintain all INDs necessary to perform its obligations under the Initial Development Plan, and to conduct communications with the applicable Regulatory Authorities with respect to such INDs. The modified version **adds uncertainty** by using \"may not\", making the responsibility unclear.",
                "location": "ARTICLE 3"
            }
        ]
    }
]